Actively Recruiting
Fertility And Sexual Function In CAH: CALLIOPE
Led by University of Roma La Sapienza · Updated on 2025-08-01
50
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
U
University of Roma La Sapienza
Lead Sponsor
U
University of Modena and Reggio Emilia
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicenter study designed to assess the effects of groundbreaking CAH therapies on a spectrum of clinical and biochemical outcomes, with a special emphasis on reproductive and sexual health. Fertility is a profound concern for individuals with CAH, given the high prevalence of gonadal dysfunction that arises from the hormonal derangements that characterize this complex disease. At our endo-ERN accredited center for rare diseases at Policlinico Umberto I, addressing these fertility issues in CAH patients represents a daily commitment. The revolution of the pharmacological management of CAH is one of the most debated topics to date. Data on the effects of novel management options for CAH on fertility are scarce, but the anecdotal improvements in sperm count and menstrual regularity reported in the latest clinical trials have significantly motivated us to design the CALLIOPE study. Thus, we aim to delve deeper into the fertility and sexual function of CAH patients, employing advanced seminal parameter evaluations, multiparametric gonadal ultrasound, and sophisticated hormonal analyses in both females and males performed by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Beyond fertility, the CALLIOPE trial aspires to provide further understanding of therapy's effects on body composition, metabolism, immune function, coagulation, and quality of life, among other factors. We will explore the immunological impact of novel CAH therapies by quantifying Peripheral Blood Mononuclear Cells (PBMCs) and analyzing transcriptomic profiles to unveil gene expression patterns and identify biomarkers that could signal therapeutic targets or disease management strategies in CAH. Moreover, seminal plasma will be used to assess the expression of adrenal miRNAs regulating steroidogenesis and metabolism. The research will be conducted at our rare disease referral center (Policlinico Umberto I, Sapienza University of Rome) in collaboration with leading centers across Italy: Modena (Università degli Studi di Modena e Reggio Emilia), Naples (Università Federico II), Rome (Ospedale Sant'Andrea) and Bologna (Alma Mater Studiorum - Università di Bologna). https://isidorilab.com/home
CONDITIONS
Official Title
Fertility And Sexual Function In CAH: CALLIOPE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients, males aged 18 to 65 years and pre-menopausal females aged 18 to 55 years
- Known or new diagnosis of Congenital Adrenal Hyperplasia (CAH)
You will not qualify if you...
- Body mass index (BMI) greater than 40 Kg/m2
- Any other condition requiring steroid treatment
- Severe liver or kidney disease
- Overt hyperthyroidism or hypothyroidism
- Malignant tumors
- Drug or alcohol abuse
- Use of drugs affecting hormone levels, such as antiandrogens
- Psychiatric diseases
- Postmenopausal women
- Women taking combined oral contraceptive pills or other contraceptives without stability for at least 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Experimental Medicine, Sapienza University of Rome
Rome, Italy, Italy, 00161
Actively Recruiting
Research Team
A
Andrea M Isidori, MD, PhD, FRCP
CONTACT
D
Davide Ferrari, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here